--- title: "15:03 ETRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit" type: "News" locale: "en" url: "https://longbridge.com/en/news/286144592.md" description: "Regencell Bioscience Holdings Limited (NASDAQ: RGC) shareholders who incurred losses may lead a securities fraud class action lawsuit. The Law Offices of Frank R. Cruz announced that investors can participate before the June 23, 2026 deadline. The lawsuit alleges that from October 28, 2024, to October 31, 2025, the company failed to disclose vulnerabilities to market manipulation, exposing investors to significant risks and misleading them about the company's operations and prospects. Interested investors can contact the law firm for more information." datetime: "2026-05-12T19:04:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286144592.md) - [en](https://longbridge.com/en/news/286144592.md) - [zh-HK](https://longbridge.com/zh-HK/news/286144592.md) --- # 15:03 ETRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit , /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC) have opportunity to lead the securities fraud class action lawsuit. **IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC), CLICK** **HERE** **BEFORE JUNE 23, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.** **What Is The Lawsuit About?** The complaint filed alleges that, between October 28, 2024 and October 31, 2025, Defendants failed to disclose to investors that: (1) Regencell was vulnerable and/or subject to market manipulation; (2) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (3) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. **Contact Us To Participate or Learn More: **If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. The Law Offices of Frank R. Cruz, Email us at: \[email protected\] Call us at: 310-914-5007 Visit our website at: www.frankcruzlaw.com Follow us for updates on Twitter: twitter.com/FRC\_LAW. If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. SOURCE The Law Offices of Frank R. Cruz, Los Angeles ### Related Stocks - [RGC.US](https://longbridge.com/en/quote/RGC.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)